Psychiatric Symptoms in Acute Intermittent Porphyria - Case Report and Course of Treatment Using Placebo
DOI:
https://doi.org/10.12775/JEHS.2025.78.57663Keywords
acute intermittent porphyria, porphobilinogen, depression, anxiety disorders, psychiatry, placeboAbstract
Introduction:
Acute intermittent porphyria is a disease inherited in an autosomal dominant manner, occurring with a frequency of 1:75,000 people. The main symptom of the disease is paroxysmal, colicky abdominal pain, which is accompanied by neuropsychiatric symptoms. For some patients, psychiatric symptoms are the only symptom of the disease. In this paper, the case of a 43-year-old patient struggling with recurrent colicky abdominal pain and depressive and anxiety disorders, which intensify during exacerbation periods, is presented, featuring an ambiguous diagnosis of porphyria in previous laboratory tests. In the treatment, glucose infusions, morphine, psychiatric and psychological therapy were used - saline solution was administered as a placebo.
Aim:
The aim of this paper is to highlight the difficulties in diagnosing psychiatric symptoms during an acute attack of porphyria, which significantly complicate its treatment, and to consider the possibility of using placebo as one of the elements in the diagnostic and therapeutic plan in order to optimize treatment and avoid complications by using smaller doses of narcotic drugs.
Review methods:
A thorough analysis of research studies available on PUBMED was conducted using the following keywords: acute intermittent porphyria; porphobilinogen; depression; anxiety disorders; psychiatry; placebo. The medical history of a 43-year-old female patient, suspected of having acute intermittent porphyria due to recurrent abdominal pain and psychiatric symptoms, was also analyzed.
Conclusion:
Our case illustrates how psychiatric symptoms can complicate the diagnosis of acute intermittent porphyria. Failing to recognize acute porphyria also carries the risk of life-threatening complications and may lead to unnecessary pharmacotherapy and stigmatization as a mental illness. This case demonstrates that placebo can be one of the components of a diagnostic and therapeutic plan of acute intermittent porphyria.
References
1. Dickey AK, Leaf RK, Balwani M. Update on the Porphyrias. Annu Rev Med. 2024 Jan 29;75:321-335. doi: 10.1146/annurev-med-042921-123602.
2. Pierach CA, Edwards PS. Neurotoxicity of delta-aminolevulinic acid and porphobilinogen. Exp Neurol. 1978 Dec;62(3):810-4. doi: 10.1016/0014-4886(78)90287-x.
3. Wang B, Bonkovsky HL, Lim JK, Balwani M. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Gastroenterology. 2023 Mar;164(3):484-491. doi: 10.1053/j.gastro.2022.11.034.
4. Bustad HJ, Kallio JP, Vorland M, Fiorentino V, Sandberg S, Schmitt C, Aarsand AK, Martinez A. Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators. Int J Mol Sci. 2021 Jan 12;22(2):675. doi: 10.3390/ijms22020675.
5. Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. Br J Haematol. 2017 Feb;176(4):527-538. doi: 10.1111/bjh.14459.
6. Bardak AE, Alada MO, Senkal N, Alibeyoğlu A, Köse M. Acute Intermittent Porphyria Attack Triggered by COVID-19 Infection. Cureus. 2023 Apr 10;15(4):e37412. doi: 10.7759/cureus.37412.
7. Ramanujam VS, Anderson KE. Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias. Curr Protoc Hum Genet. 2015 Jul 1;86:17.20.1-17.20.26. doi: 10.1002/0471142905.hg1720s86. PMID: 26132003; PMCID: PMC4640448.
8. Duque-Serrano L, Patarroyo-Rodriguez L, Gotlib D, Molano-Eslava JC. Psychiatric Aspects of Acute Porphyria: a Comprehensive Review. Curr Psychiatry Rep. 2018 Feb 2;20(1):5. doi: 10.1007/s11920-018-0867-1.
9. Hift RJ, Peters TJ, Meissner PN. A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the 'Royal Malady'. J Clin Pathol. 2012 Mar;65(3):200-5. doi: 10.1136/jclinpath-2011-200276.
10. Ellencweig N, Schoenfeld N, Zemishlany Z. Acute intermittent porphyria: psychosis as the only clinical manifestation. Isr J Psychiatry Relat Sci. 2006;43(1):52-6. PMID: 16910386.
11. Crimlisk HL. The little imitator--porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):319-28. doi: 10.1136/jnnp.62.4.319.
12. Santosh PJ, Malhotra S. Varied psychiatric manifestations of acute intermittent porphyria. Biol Psychiatry. 1994 Dec 1;36(11):744-7. doi: 10.1016/0006-3223(94)90085-x.
13. Vitória-Silva J, Mota J. Porphyria Misdiagnosed as Schizophrenia Nonresponsive to Electroconvulsive Therapy. J ECT. 2019 Jun;35(2):e20. doi: 10.1097/YCT.0000000000000563.
14. Suh Y, Gandhi J, Seyam O, Jiang W, Joshi G, Smith NL, Ali Khan S. Neurological and neuropsychiatric manifestations of porphyria. Int J Neurosci. 2019 Dec;129(12):1226-1233. doi: 10.1080/00207454.2019.1655014.
15. Pallet N, Mami I, Schmitt C, Karim Z, François A, Rabant M, Nochy D, Gouya L, Deybach JC, Xu-Dubois Y, Thervet E, Puy H, Karras A. High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. Kidney Int. 2015 Aug;88(2):386-95. doi: 10.1038/ki.2015.97.
16. Spiritos Z, Salvador S, Mosquera D, Wilder J. Acute Intermittent Porphyria: Current Perspectives And Case Presentation. Ther Clin Risk Manag. 2019 Dec 16;15:1443-1451. doi: 10.2147/TCRM.S180161.
17. Alshammary S, Dulaijan RA, Saleh K, Zakaria H, Eldamati A, Alwakeel N, Al-Mulhim A. Acute intermittent porphyria after right hemi-colectomy. Int J Surg Case Rep. 2017;40:116-119. doi: 10.1016/j.ijscr.2017.09.018.
18. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017 Aug 31;377(9):862-872. doi: 10.1056/NEJMra1608634.
19. Lissing M, Nowak G, Adam R, Karam V, Boyd A, Gouya L, Meersseman W, Melum E, Ołdakowska-Jedynak U, Reiter FP, Colmenero J,
20. Sanchez R, Herden U, Langendonk J, Ventura P,Isoniemi H, Boillot O, Braun F, Perrodin S, Mowlem E, Wahlin S; European Liver and Intestine Transplant Association. Liver Transplantation for Acute Intermittent Porphyria. Liver Transpl. 2021 Apr;27(4):491-501. doi: 10.1002/lt.25959.
21. Marsden JT, Guppy S, Stein P, Cox TM, Badminton M, Gardiner T, Barth JH, Stewart MF, Rees DC. Audit of the Use of Regular Haem Arginate Infusions in Patients with Acute Porphyria to Prevent Recurrent Symptoms. JIMD Rep. 2015;22:57-65. doi: 10.1007/8904_2015_411.
22. Walterfang M, Bonnot O, Mocellin R, Velakoulis D. The neuropsychiatry of inborn errors of metabolism. J Inherit Metab Dis. 2013 Jul;36(4):687-702. doi: 10.1007/s10545-013-9618-y.
23. Colloca L. The Placebo Effect in Pain Therapies. Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:191-211. doi: 10.1146/annurev-pharmtox-010818-021542.
24. Mark TL, Parish W. Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abuse Treat. 2019 Aug;103:58-63. doi: 10.1016/j.jsat.2019.05.001.
25. Storjord E, Dahl JA, Landsem A, Ludviksen JK, Karlsen MB, Karlsen BO, Brekke OL. Lifestyle factors including diet and biochemical biomarkers in acute intermittent porphyria: Results from a case-control study in northern Norway. Mol Genet Metab. 2019 Nov;128(3):254-270. doi: 10.1016/j.ymgme.2018.12.006.
26. Bonkovsky HL, Dixon N, Rudnick S. Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs). Mol Genet Metab. 2019 Nov;128(3):213-218. doi: 10.1016/j.ymgme.2019.03.002.
27. Dickey A, Wheeden K, Lyon D, Burrell S, Hegarty S, Falchetto R, Williams ER, Barman-Aksözen J, DeCongelio M, Bulkley A, Matos JE, Mnif T, Mora J, Ko JJ, Meninger S, Lombardelli S, Nance D. Quantifying the impact of symptomatic acute hepatic porphyria on well-being via patient-reported outcomes: Results from the Porphyria Worldwide Patient Experience Research (POWER) study. JIMD Rep. 2022 Oct 18;64(1):104-113. doi: 10.1002/jmd2.12343. Erratum in: JIMD Rep. 2023 Jul 02;64(4):300. doi: 10.1002/jmd2.12376.
28. Gorchein A. Drug treatment in acute porphyria. Br J Clin Pharmacol. 1997 Nov;44(5):427-34. doi: 10.1046/j.1365-2125.1997.t01-1-00609.x.
29. Horgan P, Jones H. Olanzapine use in acute porphyria. Int J Psychiatry Clin Pract. 2003;7(1):67-9. doi: 10.1080/13651500310001103.
Ibrahim ZY, Carney MM. Safe use of haloperidol in acute intermittent porphyria. Ann Pharmacother. 1995 Feb;29(2):200. doi: 10.1177/106002809502900221.
30. Findley H, Philips A, Cole D, Nair A. Porphyrias: implications for anaesthesia, critical care, and pain medicine. Contin Educ Anaesth Crit Care Pain. 2012 Jun;12:128–133. doi: 10.1093/bjaceaccp/mks009
31. Jensen NF, Fiddler DS, Striepe V. Anesthetic considerations in porphyrias. Anesth Analg. 1995 Mar;80(3):591-9. doi: 10.1097/00000539-199503000-00028.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Waldemar Kosiba, Dominika Prystacka-Szar, Jakub Siemko, Wojciech Kupczak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 1914
Number of citations: 0
